Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9779720 | 0.88 | OR51E2 (0.46) | CRBNOR51E2HTTFKBP5KDM4E | |
| SCHEMBL3055048 | 0.84 | CRBN (0.37) | CRBNOR51E2FKBP5ALDH1A1NOS3 | |
| SCHEMBL1423866 | 0.81 | CYP1A2 (0.44) | CRBNOR51E2HTTKDM4EALDH1A1 | |
| SCHEMBL24456693 | 0.81 | — | — | |
| SCHEMBL7030866 | 0.81 | — | — | |
| SCHEMBL13575606 | 0.81 | — | — | |
| SCHEMBL5451213 | 0.81 | — | — | |
| SCHEMBL7625438 | 0.80 | CYP1A2 (0.44) | CRBNOR51E2ALDH1A1 | |
| SCHEMBL25280759 | 0.79 | CRBN (0.40) | CRBNOR51E2FKBP5KDM4EGAA | |
| SCHEMBL11727840 | 0.78 | CYP1A2 (0.42) | HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-0951466-B1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-4604450-A | ANIONIC POLYMERIZATION OF LACTAMS; RIM; RING OPENING | THE DOW CHEMICAL COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0163954-A2 | Copolymers of lactams and azetidine-2,4-dione-based prepolymers | THE DOW CHEMICAL COMPANY (US) | 1985-12-11 | — | — | EP | disclosed |
| US-4550157-A | ANIONIC POLYMERIZATION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1985-10-29 | — | — | US | disclosed |
| US-4423204-A | HEAT RESISTANCE MOLDING MATERIALS | THE UPJOHN COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4383090-A | HIGH SPEED; COCURING AGENT OF POLYAMIDE-POLYLACTAM COPOLYMER; FILMS; CASTINGS; POTTING; ADHESIVES | DIAMOND SHAMROCK CORPORATION (US) | 1983-05-10 | — | — | US | disclosed |
| EP-0075827-A2 | Polyepoxide curing by polymercaptans plus catalytic co-curing agents | DIAMOND SHAMROCK CHEMICALS COMPANY (US) | 1983-04-06 | — | — | EP | disclosed |
| US-4368237-A | ORGANIC SOLVENT-FREE | FUJI PHOTO FILM CO., LTD. (JP) | 1983-01-11 | — | — | US | disclosed |
| US-4242783-A | Calender roll for use in super calender for magnetic tapes | FUJI PHOTO FILM CO., LTD. (JP) | 1981-01-06 | — | — | US | disclosed |
| US-4153775-A | DIHYDROXY MASKED DIISOCYANATE | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | disclosed |
| US-4128673-A | Method for super calendering magnetic recording elements | FUJI PHOTO FILM CO., LTD. (JP) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | CRBN 1668/4885OR51E2 2781/4885HTT 310/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | CRBN 174/4885OR51E2 4448/4885HTT 2477/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | CRBN 1668/4885OR51E2 2781/4885HTT 310/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | CRBN 1668/4885OR51E2 2781/4885HTT 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.